MA37949B1 - Polypeptides contenant fc ayant une glycosylation modifiée et une fonction effectrice réduite - Google Patents

Polypeptides contenant fc ayant une glycosylation modifiée et une fonction effectrice réduite

Info

Publication number
MA37949B1
MA37949B1 MA37949A MA37949A MA37949B1 MA 37949 B1 MA37949 B1 MA 37949B1 MA 37949 A MA37949 A MA 37949A MA 37949 A MA37949 A MA 37949A MA 37949 B1 MA37949 B1 MA 37949B1
Authority
MA
Morocco
Prior art keywords
binding polypeptides
effector function
reduced effector
modified glycosylation
antigen
Prior art date
Application number
MA37949A
Other languages
English (en)
Other versions
MA37949A1 (fr
Inventor
Clark Pan
Huawei Qiu
Original Assignee
Genzyme Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50278674&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA37949(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from PCT/EP2012/003819 external-priority patent/WO2013037484A2/fr
Application filed by Genzyme Corp filed Critical Genzyme Corp
Publication of MA37949A1 publication Critical patent/MA37949A1/fr
Publication of MA37949B1 publication Critical patent/MA37949B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2851—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2893—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD52
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Transplantation (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Toxicology (AREA)
  • Pathology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)

Abstract

L'invention concerne des polypeptides de liaison (par exemple des anticorps) et des conjugués médicamenteux de ceux-ci, comportant un domaine fc ayant un profil de glycosylation modifié et une fonction effectrice réduite. Dans un mode de réalisation particulier, le domaine fc comporte : un résidu asparagine à la position d'acide aminé 298, selon la numération eu; un résidu sérine ou thréonine à la position d'acide aminé 300, selon la numération eu. L'invention concerne également des acides nucléiques codant pour les polypeptides de liaison à un antigène, des vecteurs d'expression recombinants et des cellules hôtes pour la fabrication de tels polypeptides de liaison à un antigène. L'invention concerne également des procédés d'utilisation des polypeptides de liaison à un antigène selon la présente invention pour traiter une maladie.
MA37949A 2012-09-12 2013-09-12 Polypeptides contenant fc ayant une glycosylation modifiée et une fonction effectrice réduite MA37949B1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
PCT/EP2012/003819 WO2013037484A2 (fr) 2011-09-12 2012-09-12 Anticorps anti-alphabêtatcr
US201361776715P 2013-03-11 2013-03-11
PCT/US2013/059481 WO2014043361A1 (fr) 2012-09-12 2013-09-12 Polypeptides contenant fc ayant une glycosylation modifiée et une fonction effectrice réduite

Publications (2)

Publication Number Publication Date
MA37949A1 MA37949A1 (fr) 2016-05-31
MA37949B1 true MA37949B1 (fr) 2017-07-31

Family

ID=50278674

Family Applications (1)

Application Number Title Priority Date Filing Date
MA37949A MA37949B1 (fr) 2012-09-12 2013-09-12 Polypeptides contenant fc ayant une glycosylation modifiée et une fonction effectrice réduite

Country Status (34)

Country Link
EP (3) EP4223783A3 (fr)
JP (1) JP6438397B2 (fr)
KR (3) KR102185151B1 (fr)
CN (2) CN104797601B (fr)
AU (1) AU2013315499B2 (fr)
CA (1) CA2884762C (fr)
CL (1) CL2015000606A1 (fr)
CR (1) CR20150147A (fr)
CY (1) CY1120909T1 (fr)
DK (2) DK3366705T5 (fr)
DO (1) DOP2015000050A (fr)
EA (2) EA202091166A1 (fr)
EC (1) ECSP15014133A (fr)
ES (2) ES2684549T3 (fr)
FI (1) FI3366705T3 (fr)
HR (2) HRP20181354T1 (fr)
HU (2) HUE062876T2 (fr)
IL (4) IL237640B (fr)
LT (2) LT3366705T (fr)
MA (1) MA37949B1 (fr)
MX (2) MX366103B (fr)
MY (1) MY170126A (fr)
NZ (1) NZ705983A (fr)
PE (1) PE20150650A1 (fr)
PH (1) PH12015500528A1 (fr)
PL (2) PL3366705T3 (fr)
PT (2) PT2895513T (fr)
RS (2) RS57748B1 (fr)
SG (2) SG11201501521TA (fr)
SI (2) SI2895513T1 (fr)
TN (1) TN2015000085A1 (fr)
UA (1) UA116995C2 (fr)
WO (1) WO2014043361A1 (fr)
ZA (1) ZA201501417B (fr)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UY34317A (es) 2011-09-12 2013-02-28 Genzyme Corp Anticuerpo antireceptor de célula T (alfa)/ß
US9790268B2 (en) 2012-09-12 2017-10-17 Genzyme Corporation Fc containing polypeptides with altered glycosylation and reduced effector function
US9701753B2 (en) 2013-03-11 2017-07-11 Genzyme Corporation Hyperglycosylated binding polypeptides
WO2015143091A1 (fr) * 2014-03-19 2015-09-24 Genzyme Corporation Modification de la glyco-ingéniérie de fractions de ciblage spécifique à un site
AU2015243512B2 (en) 2014-04-08 2020-06-04 University Of Georgia Research Foundation Inc. Site-specific antibody-drug glycoconjugates and methods
WO2015191883A1 (fr) * 2014-06-12 2015-12-17 Dophen Biomedical Conjugués anticorps-médicament homogènes par des procédés enzymatiques
CA3205824A1 (fr) * 2014-10-09 2016-04-14 Genzyme Corporation Conjugues medicament-anticorps modifies par glycane
TW202417497A (zh) 2015-10-12 2024-05-01 美商再生元醫藥公司 活化瘦素受體的抗原結合蛋白
EP3222292A1 (fr) * 2016-03-03 2017-09-27 Heidelberg Pharma GmbH Conjugués d'amanitine
TW201815821A (zh) 2016-07-18 2018-05-01 美商再生元醫藥公司 抗茲卡病毒抗體及使用方法
LT3538554T (lt) 2016-11-08 2025-10-10 Antigeną surišantys baltymai, antagonizuojantys leptino receptorius
WO2018107116A1 (fr) * 2016-12-09 2018-06-14 Abbvie Stemcentrx Llc Procédés de réduction de la toxicité de conjugués anticorps-médicament, et compositions produites par ceux-ci
GB201717446D0 (en) 2017-10-24 2017-12-06 Evox Therapeutics Ltd Affinity purification of engineering extracellular vesicles
SG11202005146VA (en) 2017-12-18 2020-06-29 Regeneron Pharma Bispecific antigen binding molecules that bind leptin receptor and/or gp130, and methods of use thereof
PT3773713T (pt) 2018-04-06 2025-07-29 Regeneron Pharma Anticorpo agonista do recetor de leptina para usar no aumento da massa óssea num sujeito que sofre de disfunção metabólica ou de hipoleptinemia
JP1640846S (fr) * 2018-10-16 2019-09-09
CA3110377A1 (fr) 2018-11-21 2020-05-28 Regeneron Pharmaceuticals, Inc. Anticorps anti-staphylococcus et leurs utilisations
PH12021551476A1 (en) 2018-12-21 2022-04-25 Regeneron Pharma Rifamycin analogs and antibody-drug conjugates thereof
WO2020160242A1 (fr) 2019-02-01 2020-08-06 Regeneron Pharmaceuticals, Inc. Protéines de liaison à l'antigène gamma du récepteur anti-il2
CN114096559B (zh) * 2019-03-27 2026-03-20 蒂嘉特克斯公司 工程化iga抗体及其使用方法
CN120192414A (zh) 2019-04-03 2025-06-24 建新公司 具有降低的断裂的抗αβTCR结合多肽
AU2021268026A1 (en) 2020-05-08 2023-01-19 Regeneron Pharmaceuticals, Inc. VEGF traps and mini-traps and methods for treating ocular disorders and cancer
KR20230069969A (ko) 2020-09-15 2023-05-19 리제너론 파마슈티칼스 인코포레이티드 통증에 대한 lepr 아고니스트의 사용
KR20220052098A (ko) 2020-10-20 2022-04-27 주식회사 엘지에너지솔루션 마스킹 테이프를 이용한 전극 시편에 대한 물성 측정 시스템 및 이를 이용한 물성 측정 방법
KR102576252B1 (ko) * 2021-04-07 2023-09-11 아주대학교산학협력단 산화된 면역글로불린을 유효성분으로 포함하는 면역조절 기능 이상 관련 질환 예방 또는 치료용 약학적 조성물
TW202325273A (zh) * 2021-10-22 2023-07-01 美商杜夫特學院信託管理公司 靶向fap之中子捕獲劑及與其相關之用途及調配物
KR20250058123A (ko) 2022-07-29 2025-04-29 리제너론 파마슈티칼스 인코포레이티드 항-TfR:페이로드 융합 및 이의 사용 방법
CA3263388A1 (fr) 2022-07-29 2024-02-01 Regeneron Pharmaceuticals, Inc. Particules virales reciblées vers le récepteur 1 de transferrine
CN120659627A (zh) 2022-07-29 2025-09-16 瑞泽恩制药公司 用于转铁蛋白受体（tfr）介导的脑和肌肉递送的组合物和方法
EP4612184A1 (fr) 2022-11-04 2025-09-10 Regeneron Pharmaceuticals, Inc. Protéines de liaison de sous-unité auxiliaire gamma 1 du canal calcique dépendant de la tension (cacng1) et administration médiée par cacng1 au muscle squelettique
AU2023379451A1 (en) 2022-11-14 2025-05-01 Regeneron Pharmaceuticals, Inc. Anti-fgfr3 antibodies and antigen-binding fragments and methods of use thereof
KR20250116795A (ko) 2022-11-14 2025-08-01 리제너론 파마슈티칼스 인코포레이티드 별아교세포로의 섬유아세포 성장 인자 수용체 3-매개된 전달을 위한 조성물 및 방법
IL325163A (en) 2023-06-16 2026-02-01 Regeneron Pharma CD40 × CD40 dual-specific antigen-binding molecules and their application
IL326018A (en) 2023-07-28 2026-03-01 Regeneron Pharma Introduction of anti-TFR:GAA and anti-CD63:GAA for the treatment of Pompe disease
US20250049896A1 (en) 2023-07-28 2025-02-13 Regeneron Pharmaceuticals, Inc. Anti-tfr:acid sphingomyelinase for treatment of acid sphingomyelinase deficiency
TW202535925A (zh) 2023-10-25 2025-09-16 比利時商艾伯霖克斯公司 具有增強的Ｆｃ受體結合之Ｆｃ結構域變體
TW202540169A (zh) 2023-11-08 2025-10-16 法商賽諾菲公司 基於ｃｄ２５的溶酶體降解物及其用途
WO2025160324A2 (fr) 2024-01-26 2025-07-31 Regeneron Pharmaceuticals, Inc. Procédés et compositions pour utiliser des agents de déplétion des cellules plasmatiques et/ou des agents de déplétion des lymphocytes b pour supprimer une réponse d'anticorps anti-aav hôte et permettre la transduction et le redosage d'aav
US20250242018A1 (en) 2024-01-26 2025-07-31 Regeneron Pharmaceuticals, Inc. Combination immunosuppression for inhibiting an immune response and enabling immunogen administration and re-administration
WO2025184603A2 (fr) 2024-03-01 2025-09-04 Regeneron Pharmaceuticals, Inc. Utilisation d'inhibiteurs de cd40 pour inhiber une réponse immunitaire et permettre une administration et une réadministration d'immunogène
US20250276092A1 (en) 2024-03-01 2025-09-04 Regeneron Pharmaceuticals, Inc. Methods and compositions for re-dosing aav using anti-cd40 antagonistic antibody to suppress host anti-aav antibody response
EP4616869A1 (fr) * 2024-03-15 2025-09-17 Oncomatryx Biopharma, S.L. Conjugués anticorps-médicament ciblant fap

Family Cites Families (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3101690B2 (ja) 1987-03-18 2000-10-23 エス・ビィ・２・インコーポレイテッド 変性抗体の、または変性抗体に関する改良
US6780613B1 (en) 1988-10-28 2004-08-24 Genentech, Inc. Growth hormone variants
EP0627932B1 (fr) 1992-11-04 2002-05-08 City Of Hope Structure d'anticorps
GB9422383D0 (en) 1994-11-05 1995-01-04 Wellcome Found Antibodies
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
US6096871A (en) 1995-04-14 2000-08-01 Genentech, Inc. Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life
US5739277A (en) 1995-04-14 1998-04-14 Genentech Inc. Altered polypeptides with increased half-life
US6121022A (en) 1995-04-14 2000-09-19 Genentech, Inc. Altered polypeptides with increased half-life
BR9606706A (pt) 1995-10-16 1999-04-06 Unilever Nv Análogo de fragmento de anticorpo biespecífico ou bivalente uso processo para produzir o mesmo
GB9524973D0 (en) 1995-12-06 1996-02-07 Lynxvale Ltd Viral vectors
DE69738522T2 (de) 1996-08-02 2009-04-02 Bristol-Myers Squibb Co. Ein verfahren zur inhibierung immunglobulininduzierter toxizität aufgrund von der verwendung von immunoglobinen in therapie und in vivo diagnostik
WO1998023289A1 (fr) 1996-11-27 1998-06-04 The General Hospital Corporation Modulation de la fixation de l'igg au fcrn
US6277375B1 (en) 1997-03-03 2001-08-21 Board Of Regents, The University Of Texas System Immunoglobulin-like domains with increased half-lives
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
US6528624B1 (en) 1998-04-02 2003-03-04 Genentech, Inc. Polypeptide variants
US6242195B1 (en) 1998-04-02 2001-06-05 Genentech, Inc. Methods for determining binding of an analyte to a receptor
ATE375365T1 (de) 1998-04-02 2007-10-15 Genentech Inc Antikörper varianten und fragmente davon
GB9809951D0 (en) 1998-05-08 1998-07-08 Univ Cambridge Tech Binding molecules
EP1105427A2 (fr) 1998-08-17 2001-06-13 Abgenix, Inc. Production de molecules modifiees avec demi-vie serique prolongee
EP1006183A1 (fr) 1998-12-03 2000-06-07 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Récepteurs Fc recombinantes et solubles
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
PL209392B1 (pl) 1999-01-15 2011-08-31 Genentech Inc Przeciwciało, komórka gospodarza, sposób wytwarzania przeciwciała oraz zastosowanie przeciwciała
CA2410551A1 (fr) 2000-06-30 2002-01-10 Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw (Vib) Proteines de fusion heterodimeres
GB0029407D0 (en) 2000-12-01 2001-01-17 Affitech As Product
US7083784B2 (en) 2000-12-12 2006-08-01 Medimmune, Inc. Molecules with extended half-lives, compositions and uses thereof
US6900292B2 (en) * 2001-08-17 2005-05-31 Lee-Hwei K. Sun Fc fusion proteins of human erythropoietin with increased biological activities
US20040002587A1 (en) * 2002-02-20 2004-01-01 Watkins Jeffry D. Fc region variants
US20040132101A1 (en) * 2002-09-27 2004-07-08 Xencor Optimized Fc variants and methods for their generation
JP2006502091A (ja) 2002-03-01 2006-01-19 イミューノメディクス、インコーポレイテッド クリアランス速度を高めるための二重特異性抗体点変異
DK1534335T4 (en) 2002-08-14 2015-10-05 Macrogenics Inc FCGAMMARIIB-SPECIFIC ANTIBODIES AND PROCEDURES FOR USE THEREOF
EP1553975B8 (fr) 2002-09-27 2023-04-12 Xencor, Inc. Variants fc optimises et methodes destinees a leur generation
DK1562972T3 (da) 2002-10-15 2010-12-06 Facet Biotech Corp Modifikation af FcRn-bindingsaffiniteter eller serumhalveringstider for antistoffer ved mutagenese
CA2512729C (fr) 2003-01-09 2014-09-16 Macrogenics, Inc. Identification et elaboration d'anticorps avec des regions du variant fc et procedes d'utilisation associes
DK1641823T3 (da) * 2003-06-12 2011-12-12 Lilly Co Eli GLP-1-analog fusionsproteiner
US8399618B2 (en) * 2004-10-21 2013-03-19 Xencor, Inc. Immunoglobulin insertions, deletions, and substitutions
GB0324368D0 (en) 2003-10-17 2003-11-19 Univ Cambridge Tech Polypeptides including modified constant regions
WO2005047327A2 (fr) 2003-11-12 2005-05-26 Biogen Idec Ma Inc. Variants de polypeptide se liant au recepteur fc neonatal (fcrn), proteines de liaison fc dimeres et techniques associees
EP1697520A2 (fr) 2003-12-22 2006-09-06 Xencor, Inc. Polypeptides fc a nouveaux sites de liaison de ligands fc
SI1706424T1 (sl) 2004-01-12 2010-01-29 Applied Molecular Evolution Variante fc regij
EP1737890A2 (fr) 2004-03-24 2007-01-03 Xencor, Inc. Variantes d'immunoglobuline a l'exterieur de la region fc
WO2005123780A2 (fr) 2004-04-09 2005-12-29 Protein Design Labs, Inc. Modification des affinites de liaison pour le fcrn ou de la demi-vie serique d'anticorps par mutagenese
WO2006085967A2 (fr) 2004-07-09 2006-08-17 Xencor, Inc. Anticorps monoclonaux optimises anti-cd20 a variants fc
EP2471813B1 (fr) 2004-07-15 2014-12-31 Xencor, Inc. Variantes optimisées de Fc
WO2006036922A2 (fr) * 2004-09-27 2006-04-06 Centocor, Inc. Corps mimetiques srage, compositions, et methodes d'utilisation
WO2006047350A2 (fr) 2004-10-21 2006-05-04 Xencor, Inc. Variants d'immunoglobuline igg a fonction effectrice optimisee
JP2008537941A (ja) * 2005-03-31 2008-10-02 ゼンコー・インコーポレイテッド 最適化特性を有するＦｃ変異体
BRPI0611445A2 (pt) * 2005-05-09 2010-09-08 Glycart Biotechnology Ag molécula de ligação a antìgeno glicomanipulada, polinucleotìdeo, polipeptìdeo, vetor, célula hospedeira, método para produção, uso e composição farmacêutica
WO2006130834A2 (fr) 2005-05-31 2006-12-07 Board Of Regents, The University Of Texas System Molecules d'immunoglobuline ayant des proprietes ameliorees
PT1896071E (pt) 2005-06-30 2015-07-09 Janssen Biotech Inc Métodos e composições com melhorias na atividade terapêutica
US7612181B2 (en) 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
US8460364B2 (en) 2006-07-20 2013-06-11 Orbusneich Medical, Inc. Bioabsorbable polymeric medical device
EP2125893A2 (fr) * 2007-01-23 2009-12-02 Xencor, Inc. Anticorps cd40 optimisés et leurs procédés d'utilisation
EP2050764A1 (fr) 2007-10-15 2009-04-22 sanofi-aventis Nouveau format d'anticorps bispécifique polyvalent
US20110137011A1 (en) * 2008-04-21 2011-06-09 Novo Nordisk A/S Hyperglycosylated human coagulation factor ix
MX352889B (es) * 2011-02-25 2017-12-13 Chugai Pharmaceutical Co Ltd Anticuerpo de fc especifico para fcyriib.
TWI743461B (zh) 2011-03-28 2021-10-21 法商賽諾菲公司 具有交叉結合區定向之雙重可變區類抗體結合蛋白
UY34317A (es) * 2011-09-12 2013-02-28 Genzyme Corp Anticuerpo antireceptor de célula T (alfa)/ß

Also Published As

Publication number Publication date
KR102426488B1 (ko) 2022-07-28
FI3366705T3 (fi) 2023-07-28
MX2019007753A (es) 2019-09-09
CN110590953A (zh) 2019-12-20
AU2013315499A1 (en) 2015-04-02
KR20200136044A (ko) 2020-12-04
AU2013315499B2 (en) 2018-08-09
CR20150147A (es) 2015-05-29
SI2895513T1 (sl) 2018-11-30
SG11201501521TA (en) 2015-03-30
IL237640B (en) 2019-12-31
UA116995C2 (uk) 2018-06-11
LT2895513T (lt) 2018-09-10
RS57748B1 (sr) 2018-12-31
HRP20230623T1 (hr) 2023-09-29
EP2895513B1 (fr) 2018-05-23
CA2884762A1 (fr) 2014-03-20
MX366103B (es) 2019-06-27
RS64317B1 (sr) 2023-08-31
CN104797601B (zh) 2019-08-30
PH12015500528A1 (en) 2015-05-04
ES2950509T3 (es) 2023-10-10
KR102185151B1 (ko) 2020-12-01
PT2895513T (pt) 2018-10-08
IL276866B (en) 2021-10-31
CL2015000606A1 (es) 2015-11-13
PE20150650A1 (es) 2015-05-26
HRP20181354T1 (hr) 2018-10-19
BR112015005352A2 (pt) 2017-08-08
IL237640A0 (en) 2015-04-30
IL271027A (en) 2020-01-30
KR20220110855A (ko) 2022-08-09
TN2015000085A1 (en) 2016-06-29
CY1120909T1 (el) 2019-12-11
NZ705983A (en) 2018-06-29
PT3366705T (pt) 2023-07-19
EP2895513A1 (fr) 2015-07-22
MA37949A1 (fr) 2016-05-31
EP4223783A3 (fr) 2023-11-15
IL276866A (en) 2020-10-29
CN104797601A (zh) 2015-07-22
LT3366705T (lt) 2023-07-25
WO2014043361A1 (fr) 2014-03-20
KR20150054931A (ko) 2015-05-20
HUE039337T2 (hu) 2018-12-28
HUE062876T2 (hu) 2023-12-28
EA202091166A1 (ru) 2021-04-30
IL286766A (en) 2021-10-31
EP3366705B1 (fr) 2023-05-03
EP3366705A1 (fr) 2018-08-29
DK2895513T3 (en) 2018-09-03
EA035987B1 (ru) 2020-09-09
SG10201701831VA (en) 2017-05-30
JP2015533490A (ja) 2015-11-26
DOP2015000050A (es) 2015-04-15
JP6438397B2 (ja) 2018-12-12
EP4223783A2 (fr) 2023-08-09
PL2895513T3 (pl) 2018-11-30
IL271027B (en) 2020-09-30
EA201590545A1 (ru) 2015-08-31
SI3366705T1 (sl) 2023-08-31
DK3366705T3 (da) 2023-07-31
HK1207389A1 (en) 2016-01-29
ES2684549T3 (es) 2018-10-03
MX2015003234A (es) 2015-11-16
ECSP15014133A (es) 2017-02-24
PL3366705T3 (pl) 2023-09-18
DK3366705T5 (da) 2024-09-30
ZA201501417B (en) 2016-12-21
CA2884762C (fr) 2022-07-19
MY170126A (en) 2019-07-05

Similar Documents

Publication Publication Date Title
MA37949A1 (fr) Polypeptides contenant fc ayant une glycosylation modifiée et une fonction effectrice réduite
Wilmarth et al. Two-dimensional liquid chromatography study of the human whole saliva proteome
Bee et al. Trace levels of the CHO host cell protease cathepsin D caused particle formation in a monoclonal antibody product
Osbourn et al. HpARI protein secreted by a helminth parasite suppresses interleukin-33
ZA202409972B (en) Fcrn antagonists and methods of use
MA34738B1 (fr) Neutralisation d'anticorps anti-ccl20
EA201500952A1 (ru) Способы очистки рекомбинантного adamts13 и других белков и их композиции
MA33757B1 (fr) Protéines de liaison à l'antigène de l'il-23 humaine
EA200970231A1 (ru) СПОСОБ ОЧИСТКИ Fc-СОДЕРЖАЩИХ БЕЛКОВ
TW201613970A (en) Compositions and methods relating to universal glycoforms for enhanced antibody efficacy
EA200700751A1 (ru) Способы и композиции для улучшения продуцирования рекомбинантного белка
MA35345B1 (fr) Proteines de liaisons a un antigene ayant une liaison accrue a fcrn
MA41759A (fr) Inclusion de l'exon 2, induite par antisens, dans une alpha-glucosidase acide
WO2016057739A1 (fr) Procédé pour diminuer les particules sub-visibles au sein d'une formulation pharmaceutique
WO2007133623A3 (fr) Agent de diagnostic peptidique pour la maladie de lyme
MX336715B (es) Purificacion de iduronato-2-sulfatasa.
MA38828A1 (fr) Anticorps dirigés contre l'inhibiteur des activateurs du plasminogène de type 1 (pai-1) et leurs utilisations
WO2010065407A3 (fr) Anticorps de lamproie recombinés d'affinité élevée sélectionnés au moyen d'une plate-forme de présentation en surface de levure
EP4251130A1 (fr) Compositions et procédés d'épuisement sélectif de molécules cibles
Sfera et al. Long COVID as a tauopathy: of “Brain Fog” and “Fusogen Storms”
Luo et al. Vaccination with antigenically complex hemagglutinin mixtures confers broad protection from influenza disease
Ivleva et al. Investigation of sequence clipping and structural heterogeneity of an HIV broadly neutralizing antibody by a comprehensive LC-MS analysis
Brand et al. The interaction of the antitoxin DM43 with a snake venom metalloproteinase analyzed by mass spectrometry and surface plasmon resonance
WO2011015916A3 (fr) Vecteurs et composés pour expression d'infliximab recombinant
PL1961821T3 (pl) Erytropoetynowe białko fuzyjne